Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500 for Powerlifters — Recovery & Strength Science

TB-500 for Powerlifters — Recovery & Strength Science A 2019 study published in the Journal of Applied Physiology found that tendon remodeling rates in strength athletes lag muscle hypertrophy by 8–12 weeks. Meaning the structural tissue connecting muscle to b

By Recovery & Performance Peptides Editorial Team

TB-500 for Powerlifters — Recovery & Strength Science

A 2019 study published in the Journal of Applied Physiology found that tendon remodeling rates in strength athletes lag muscle hypertrophy by 8–12 weeks. Meaning the structural tissue connecting muscle to bone can't keep pace with the forces generated during heavy compound lifts. This mismatch is why powerlifters experience chronic elbow tendinopathy, patellar tendinitis, and rotator cuff impingement at rates far exceeding general athletes. TB-500 (thymosin beta-4 fragment) addresses this gap by upregulating actin polymerization and promoting angiogenesis in connective tissue. Mechanisms that accelerate collagen deposition where mechanical stress concentrates.

Our team has worked with athletes navigating this exact bottleneck. The difference between managing nagging joint pain and resolving it structurally comes down to whether recovery targets inflammation alone or the underlying tissue architecture TB-500 rebuilds.

What is TB-500 and how does it support powerlifting recovery?

TB-500 is a synthetic analogue of thymosin beta-4, a 43-amino-acid peptide that regulates cell migration, differentiation, and angiogenesis during tissue repair. In powerlifters, it accelerates tendon and ligament healing by promoting fibroblast migration to injury sites and increasing vascular endothelial growth factor (VEGF) expression, which delivers oxygen and nutrients to structurally compromised tissue. Clinical models show TB-500 reduces inflammation markers (IL-6, TNF-alpha) while simultaneously upregulating collagen type I synthesis. The specific protein matrix that gives tendons tensile strength under load.

Most recovery protocols address acute inflammation without rebuilding the damaged tissue itself. TB-500 shifts the mechanism from symptom suppression to structural repair. Which is why competitive lifters use it during deload phases when tendon healing can occur without continuous mechanical disruption. This article covers the biological pathways TB-500 activates, the dosing protocols that align with heavy training cycles, and the recovery timeline powerlifters should expect when integrating it into off-season or injury rehab phases.

TB-500 Mechanism: How It Targets Powerlifting-Specific Damage

Powerlifting creates a unique injury profile: high-force eccentric loading during squats and deadlifts generates microtrauma at the muscle-tendon junction, where contractile tissue transitions to collagenous connective tissue. This zone has limited vascular supply compared to muscle bellies, which is why tendon injuries heal slower and recur more frequently than muscle strains. TB-500 works by binding to actin. A structural protein in all cells. And promoting its polymerization into organized filaments that guide cell migration during wound healing.

When tissue is damaged, the body releases chemotactic signals that recruit fibroblasts (cells responsible for collagen synthesis) and endothelial cells (which form new blood vessels). TB-500 amplifies this process by enhancing the migratory capacity of these cells, ensuring they reach the injury site faster and in greater numbers. Research published in the American Journal of Sports Medicine demonstrated that thymosin beta-4 administration increased collagen deposition density by 34% compared to control groups in tendon injury models. A statistically significant improvement in structural repair rates.

For powerlifters, this translates to faster resolution of chronic conditions like golfer's elbow (medial epicondylitis), which stems from repetitive high-load gripping during deadlifts, and patellar tendinopathy, caused by eccentric quad loading during heavy squats. TB-500 doesn't just reduce pain. It rebuilds the tissue architecture that mechanical stress degrades over time.

Dosing Protocols TB-500 for Powerlifters in Training and Recovery Cycles

Standard TB-500 dosing for connective tissue repair follows a loading phase of 5–10mg per week (split into 2–3 subcutaneous injections) for 4–6 weeks, followed by a maintenance phase of 2–5mg per week. The loading phase saturates tissue with thymosin beta-4, initiating the cellular migration and angiogenesis processes that drive structural healing. Maintenance dosing sustains these effects without requiring the higher concentrations needed to kickstart repair.

Powerlifters typically time TB-500 cycles around deload weeks or off-season blocks when training volume drops and mechanical load on tendons decreases. This allows the peptide's repair mechanisms to operate without continuous microtrauma interrupting collagen remodeling. Injecting TB-500 during peak training phases yields diminished results because high-frequency heavy lifts re-injure tissue faster than the peptide can repair it. The most effective protocol pairs TB-500 with strategic programming: reduce squat and deadlift frequency to twice weekly during the loading phase, prioritize accessory work that doesn't load compromised joints, and reintroduce max-effort lifts only after 6–8 weeks of consistent dosing.

BPC-157 is often stacked with TB-500 because it accelerates gastric and mucosal healing. Relevant for powerlifters using NSAIDs to manage training-related inflammation, which can cause GI distress over time. The two peptides target overlapping but distinct pathways: TB-500 promotes angiogenesis and fibroblast migration, while BPC-157 stabilizes nitric oxide pathways and enhances growth hormone receptor expression. We've found that combining them during injury rehab phases produces faster symptom resolution than either peptide alone, though the evidence base for synergistic effects remains largely anecdotal rather than clinically validated.

TB-500 for Powerlifters: Tendon, Ligament, and Joint Recovery Timelines

Tendon healing follows a predictable three-phase sequence: inflammation (0–7 days), proliferation (7–21 days), and remodeling (21 days to 12+ months). TB-500 shortens the proliferation phase by accelerating fibroblast recruitment and collagen synthesis, but it cannot bypass the remodeling phase. The period when newly deposited collagen realigns along lines of mechanical stress to restore tensile strength. Clinical data suggests TB-500 reduces total healing time by 20–30% in soft tissue injuries, but this still means 8–12 weeks for moderate tendinopathy and 16–24 weeks for severe ligament damage.

Powerlifters often expect peptides to deliver immediate pain relief, but TB-500 operates on a structural timeline. Not a symptom suppression timeline. Pain reduction typically occurs 3–5 weeks into a loading protocol as inflammation markers drop and tissue vascularization improves, but full functional recovery requires continued dosing through the remodeling phase. Stopping TB-500 after 4 weeks because pain has diminished leaves the repair process incomplete, which is why re-injury rates spike when lifters return to max-effort training too early.

For chronic conditions like Achilles tendinopathy or rotator cuff tendinitis. Both prevalent in competitive powerlifters. TB-500 should be viewed as a 12–16 week commitment minimum. Acute strains (muscle belly tears, minor ligament sprains) respond faster, often showing functional improvement within 6–8 weeks. The peptide doesn't eliminate the need for progressive loading rehab protocols; it accelerates the biological readiness of tissue to handle mechanical stress, but strength and coordination must still be rebuilt through controlled movement patterns.

TB-500 for Powerlifters: [Type] Comparison

TB-500

Actin polymerization, angiogenesis promotion, fibroblast migration

Tendons, ligaments, muscle-tendon junction

5–10mg/week loading, 2–5mg/week maintenance

Chronic tendinopathy, ligament sprains, joint instability from repetitive high-load training

Best-in-class for structural tendon repair; requires 6+ weeks to show measurable effect

BPC-157

Nitric oxide stabilization, VEGF upregulation, growth hormone receptor activation

Muscle tissue, gastric mucosa, ligaments

250–500mcg/day subcutaneous

Acute muscle strains, GI protection during NSAID use, faster symptom relief than TB-500

Faster subjective pain reduction but weaker evidence for long-term structural repair

GHK-Cu

Copper peptide complex, collagen and elastin synthesis, antioxidant activity

Skin, fascia, minor soft tissue injuries

1–3mg/day subcutaneous or topical

Superficial tissue repair, cosmetic recovery, minor fascia damage

Limited penetration to deep connective tissue; not ideal for major tendon injuries

Mechanical Loading Alone

Progressive tensile stress triggers mechanotransduction pathways

All connective tissue types

Gradual load increases over 12–16 weeks

Essential for all injury rehab regardless of peptide use

No peptide can replace controlled eccentric loading; TB-500 accelerates readiness for load

Key Takeaways

TB-500 accelerates tendon and ligament repair by promoting fibroblast migration and increasing collagen type I synthesis at injury sites, reducing total healing time by 20–30% in soft tissue injuries.

Standard dosing follows a 4–6 week loading phase at 5–10mg per week, then maintenance at 2–5mg per week. Timing cycles around deload weeks maximizes repair without continuous microtrauma.

Tendon remodeling timelines remain 8–12 weeks minimum for moderate tendinopathy regardless of TB-500 use; the peptide shortens proliferation but cannot bypass the structural remodeling phase.

BPC-157 stacks synergistically with TB-500 for faster symptom relief, though evidence for combined structural benefits remains largely anecdotal rather than clinically validated.

Chronic conditions like patellar tendinitis and rotator cuff tendinopathy require 12–16 week TB-500 protocols minimum; stopping after 4 weeks because pain diminished leaves tissue repair incomplete.

What If: TB-500 for Powerlifters Scenarios

What If I Start TB-500 During a Peak Training Block?

Don't. TB-500 promotes tissue repair through fibroblast migration and collagen synthesis, but these processes require reduced mechanical load to operate effectively. Injecting TB-500 while squatting and deadlifting at 85%+ of your 1RM four times per week creates a cycle of continuous microtrauma that interrupts collagen remodeling before it can strengthen tissue. The peptide can't outpace the damage rate during high-volume training. Schedule TB-500 loading phases during deload weeks or off-season blocks when training volume drops by 40–50% and intensity stays moderate.

What If My Tendon Pain Disappears After 3 Weeks — Can I Stop Dosing?

No. Pain reduction reflects decreased inflammation and improved tissue vascularization, but the structural remodeling phase. Where collagen realigns along lines of mechanical stress. Takes 8–12 weeks minimum. Stopping TB-500 after symptom relief leaves newly deposited collagen in a disorganized matrix that lacks tensile strength, which is why re-injury rates spike when lifters return to max-effort training prematurely. Continue dosing through at least 8 weeks of a loading + maintenance protocol, and reintroduce heavy lifts gradually using progressive overload principles.

What If I'm Already Using BPC-157 — Does Adding TB-500 Matter?

Yes, if you're targeting deep connective tissue injuries like tendinopathy or ligament sprains. BPC-157 accelerates muscle belly healing and provides faster subjective pain relief through nitric oxide stabilization, but its effects on dense collagenous tissue (tendons, ligaments) are less robust than TB-500's direct promotion of fibroblast migration and angiogenesis. We've seen the combination work best for powerlifters managing both acute muscle strains and chronic joint issues. BPC-157 handles the muscle side, TB-500 handles the tendon side. If budget or injection frequency is a constraint, prioritize TB-500 for structural tendon damage and BPC-157 for acute muscle tears.

The Structural Truth About TB-500 for Powerlifters

Here's the honest answer: TB-500 won't keep you training heavy while injured. It's not a performance enhancer, it's not a pain blocker, and it won't let you squat through a partial patellar tendon tear without consequences. What it does. And this is the only reason it matters for powerlifters. Is rebuild the structural tissue that high-force eccentric loading degrades faster than your body can repair it naturally.

The marketing around peptides in strength sports leans heavily on

Frequently Asked Questions

TB-500 promotes fibroblast migration to damaged tendon tissue and upregulates collagen type I synthesis — the specific protein matrix that gives tendons tensile strength under load. It also increases VEGF expression, which improves vascularization in poorly supplied connective tissue zones like the muscle-tendon junction. This accelerates structural repair rather than just suppressing inflammation, which is why it’s effective for chronic conditions like patellar tendinitis and golfer’s elbow that stem from repetitive high-force loading during squats and deadlifts.

You should deload. TB-500’s repair mechanisms — fibroblast migration, collagen remodeling, angiogenesis — require reduced mechanical load to operate effectively. Training at 85%+ intensity four times per week creates continuous microtrauma that interrupts tissue repair faster than the peptide can rebuild it. The most effective protocol schedules TB-500 loading phases during deload weeks or off-season blocks when training volume drops 40–50% and intensity stays moderate, allowing the peptide’s effects to compound without constant re-injury.

Standard dosing follows a loading phase of 5–10mg per week split into 2–3 subcutaneous injections for 4–6 weeks, then a maintenance phase of 2–5mg per week. The loading phase saturates tissue with thymosin beta-4 to initiate cellular migration and angiogenesis, while maintenance sustains these effects. Most powerlifters inject Monday, Wednesday, Friday during loading, then reduce to twice weekly during maintenance. Total protocol length should be 12–16 weeks for chronic tendinopathy, 6–8 weeks for acute strains.

Pain reduction typically occurs 3–5 weeks into a loading protocol as inflammation markers drop and tissue vascularization improves, but full functional recovery requires 8–12 weeks minimum for tendon injuries and up to 24 weeks for severe ligament damage. TB-500 operates on a structural timeline — it accelerates the proliferation phase of healing but cannot bypass the remodeling phase where collagen realigns along lines of mechanical stress. Subjective pain relief occurs before structural repair is complete, which is why stopping early leads to high re-injury rates.

TB-500 promotes actin polymerization, fibroblast migration, and angiogenesis, making it highly effective for deep connective tissue repair in tendons and ligaments. BPC-157 stabilizes nitric oxide pathways and enhances growth hormone receptor expression, providing faster subjective pain relief and better outcomes for muscle belly tears and gastric protection during NSAID use. The two peptides target overlapping but distinct pathways — TB-500 is superior for structural tendon repair, BPC-157 for acute muscle strains. Many competitive lifters stack both during injury rehab phases.

TB-500 is generally well-tolerated with minimal reported side effects in clinical and anecdotal contexts. Injection site reactions (redness, mild swelling) occur occasionally but resolve within 24–48 hours. Because TB-500 promotes angiogenesis, theoretical concerns exist about accelerating growth in pre-existing tumors or vascular abnormalities, though no clinical evidence supports this risk in healthy populations. Powerlifters should avoid TB-500 if they have a known history of cancer or undiagnosed masses. Standard subcutaneous injection hygiene eliminates most practical risks.

TB-500 is primarily a repair tool, not a prevention tool. It accelerates healing in damaged tissue by promoting fibroblast migration and collagen synthesis, but it does not increase baseline tendon tensile strength or elasticity in healthy tissue. Powerlifters looking to prevent tendinopathy should focus on progressive overload principles, adequate recovery between heavy sessions, and eccentric loading protocols that strengthen tendons over time. TB-500 becomes relevant once microtrauma accumulates into chronic inflammation or partial tears that exceed the body’s natural repair capacity.

Non-response typically stems from continuing high-intensity training during the TB-500 protocol, which re-injures tissue faster than the peptide can repair it. TB-500 requires reduced mechanical load to allow collagen remodeling without continuous microtrauma. Other common causes include dosing below the 5mg/week threshold during loading (which doesn’t saturate tissue adequately), stopping after 3–4 weeks when pain diminishes but structural repair remains incomplete, or using low-purity peptides from unverified suppliers. If training volume and intensity don’t drop during the loading phase, TB-500 produces minimal measurable effect.

TB-500 (thymosin beta-4) is prohibited under the World Anti-Doping Agency (WADA) code as a peptide hormone and growth factor, which means it is banned in-competition and out-of-competition for athletes subject to WADA testing. Most national and international powerlifting federations — including the International Powerlifting Federation (IPF) — follow WADA guidelines. Untested federations typically do not restrict TB-500 use. Athletes competing in tested federations should confirm their federation’s specific prohibited substance list and avoid TB-500 during both training and competition phases to remain compliant.

Lyophilized TB-500 should be stored at −20°C (freezer) before reconstitution. Once reconstituted with bacteriostatic water, store at 2–8°C (refrigerator) and use within 28 days — temperature excursions above 8°C cause irreversible peptide degradation. Reconstitute by injecting bacteriostatic water slowly down the inside wall of the vial to avoid foaming, then gently swirl (never shake) until powder dissolves completely. Use insulin syringes for subcutaneous administration, rotating injection sites to prevent localized irritation. Proper cold-chain storage is critical — degraded TB-500 loses efficacy without visible signs of contamination.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

TB-500 Dosing and Administration for Tendon Repair

Standard TB-500 protocols for soft tissue repair use 2.5–5mg administered subcutaneously twice per week. The peptide has a half-life of approximately 10 days, meaning therapeutic plasma levels persist throughout the dosing interval. Dosing above 5mg per injection does not appear to accelerate results. The angiogenic response plateaus once VEGF expression saturates. The typical treatment duration is 4–6 weeks, which aligns with collagen synthesis timelines. Type I collagen deposition peaks between weeks 3 and 6 post-injury in animal models, and TB-500's angiogenic effects are most valuable during this window. Starting TB-500 during the acute inflammatory phase (first 7–10 days post-injury) is less effective because the tissue hasn't yet entered the proliferative repair stage. Reconstitution requires bacteriostatic water at a 1:1 or 2:1 ratio (2mg peptide per 1mL water is standard). Once reconstituted, TB-500 must be refrigerated at 2–8°C and used within 28 days. Peptides are heat-sensitive, and any temperature excursion above 8°C causes irreversible structural degradation. Injection sites rotate between subcutaneous fat deposits (abdomen, thigh). The peptide distributes systemically, so local injection near the elbow provides no additional benefit. Our experience with research-grade peptides shows that purity verification matters. Real Peptides uses small-batch synthesis with exact amino-acid sequencing to guarantee consistency. Every vial undergoes third-party mass spectrome…
STORAGE

Storage, Reconstitution, and Peptide Stability

TB-500 is supplied as a lyophilized (freeze-dried) powder that must be stored at −20°C before reconstitution. Room temperature storage degrades the peptide within weeks, and refrigeration (2–8°C) only extends viability to 60–90 days in powder form. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), the solution must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C during storage or transport causes irreversible protein denaturation. The peptide's tertiary structure unfolds, rendering it biologically inactive even though visual appearance may remain unchanged. Post-surgery patients researching TB-500 often underestimate how fragile peptides are compared to small-molecule drugs. Unlike oral medications that tolerate ambient temperature, peptides are large proteins held together by weak hydrogen bonds that break under heat stress. A vial left out overnight at 22°C loses approximately 15–20% potency per 24-hour period. Within three days at room temperature, you're injecting mostly inactive peptide fragments. There's no home test for potency loss; by the time you realize the peptide isn't working, you've already wasted weeks of the optimal healing window. Reconstitution sterility is the second failure point. Use only bacteriostatic water for injection (not sterile saline, not distilled water). The benzyl alcohol preservative prevents bacterial growth in multi-dose vials. Inject the water slowly down the side of the vial to avo…
02

Question drills

Open a question for its connected answer.

01What If TB-500 Loses Potency During Storage or Handling?+

Lyophilised TB-500 remains stable at −20°C for 12–24 months when stored properly. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C or exposure to repeated freeze-thaw cycles causes irreversible peptide degradation. In vitro researchers should aliquot reconstituted peptide into single-use volumes to avoid contamination and degradation from repeated handling. Real Peptides provides all peptides in lyophilised form with storage guidelines that preserve structural integrity across extended research timelines.

SOURCE / realpeptides.co ↗
02What if reconstituted TB-500 was stored at room temperature instead of refrigerated — how quickly does potency degrade?+

Reconstituted TB-500 stored at room temperature (20–25°C) loses approximately 10–15% potency within 48 hours and 30–40% within one week due to peptide bond hydrolysis and oxidative degradation of methionine residues at positions 6 and 44. Refrigeration at 2–8°C slows degradation to <5% loss over 28 days. The visible sign of degradation is increased solution turbidity as denatured peptide aggregates, but potency loss begins before turbidity appears. A clear solution is not confirmation of intact peptide. Any temperature excursion above 8°C for more than 24 hours renders the vial suspect. If refrigeration fails, the peptide should be discarded rather than risk administering a partially degraded product with unpredictable pharmacokinetics.

SOURCE / realpeptides.co ↗
03What If Your Wound Closure Data Shows No Difference Between TB-500 and Control Groups?+

Verify peptide storage conditions first. Reconstituted TB-500 stored above 8°C loses bioactivity rapidly. Request a certificate of analysis (CoA) from your peptide supplier showing HPLC purity above 98% and confirm the peptide was stored at −20°C before reconstitution. If storage was correct, check your dosing schedule. Single-dose protocols rarely show significant effects because TB-500 clears before the proliferative phase begins. Repeat the study with dosing every 48 hours through Day 10.

SOURCE / realpeptides.co ↗
04What If Reconstituted TB-500 Was Left at Room Temperature Overnight?+

Discard the vial and prepare a fresh dose. TB-500's protein structure begins denaturing at temperatures above 8°C. A single 8-hour room temperature exposure reduces bioactivity by an estimated 20–40% based on similar peptide stability data. The peptide may still appear clear and unchanged visually, but denaturation is a molecular-level event that home storage cannot detect. No peptide is worth the cost of injecting a degraded compound with unknown potency.

SOURCE / realpeptides.co ↗
05What If I'm Only Dealing with a Single Tendon Tear — Is the Stack Overkill?+

For a single, isolated tendon or ligament injury, BPC-157 alone is often sufficient. The localized mechanism directly addresses collagen synthesis at the tear site, and adding TB-500's systemic effect doesn't significantly accelerate healing in this scenario. A 2019 study in the Journal of Orthopaedic Research found that BPC-157 administered alone reduced Achilles tendon healing time by 40% in animal models. TB-500 didn't add measurable benefit when the injury was confined to one site. Save the cost and complexity unless systemic inflammation or vascular repair is also a concern.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

What the Evidence Actually Shows (and at What Level)

Here is the honest tier of evidence, from strongest to weakest as it applies to the spinal cord. Direct spinal cord injury studies exist — but only in rodents. The most directly relevant work is a rat study reporting beneficial effects of Tβ4 on spinal cord injury. In a compression-injury model, Tβ4 (or saline control) was given by intraperitoneal injection starting 30 minutes, 3 days, or 5 days after injury. The Tβ4-treated animals showed improved locomotor recovery on the Basso–Beattie–Bresnahan (BBB) open-field scale and on footprint analysis, and histology at 7 days showed significantly more surviving neurons and oligodendrocytes than saline controls. Myelin basic protein, a marker of mature myelinating oligodendrocytes, was reported roughly 58% higher in treated animals.1 This is a real, peer-reviewed positive result — and it is a single-species, small-animal study using the full-length protein. Adjacent CNS-injury studies reinforce a signal — still rodents, still full-length. In traumatic brain injury (TBI) models, Xiong, Mahmood, Chopp and colleagues reported that delayed Tβ4 treatment (6 mg/kg intraperitoneally, beginning at day 1 and repeated every 3 days, or initiated as late as 6 hours post-injury) improved neurological scores and spatial learning in the Morris water maze, did not change the raw lesion volume, but reduced hippocampal cell loss and enhanced angiogenesis, neurogenesis, and oligodendrogenesis.28 In an embolic stroke model, Tβ4 improved functional neurological outcome.9 Cell-culture work showed Tβ4 protecting spinal cord-derived neural stem/progenitor cells from oxidative-stress injury via the TLR4/MyD88 pathway, dose-dependently improving viability.10 A body of review literature summarizes these as a coherent “restorative/regenerative” hypothesis for neurological injury.7 Human data on Tβ4 exist — but not for the spinal cord. The furthest Tβ4 has advanced clinically is as an ophthalmic and dermal agent, not a neurological one. A formulation of full-length Tβ4 (RGN-259, developed by RegeneRx and partners) reached Phase 3 trials for eye-surface disease. One Phase 3 study in neurotrophic keratopathy reported a corneal-healing trend favoring RGN-259 that did not reach statistical significance (complete healing in 6/10 on RGN-259 vs 1/8 on placebo, p = 0.066),11 while a separate European Phase 3 trial (SEER-3) missed its primary endpoint, attributed partly to an unexpectedly strong placebo response.12 Across the ophthalmic development program the eye-drop was reported to be generally well tolerated.1112 None of this is spinal cord data, and none of it validates systemic injection of a fragment for nerve regeneration. A useful way to visualize this is to rank each evidence source by how directly it bears on the title question — TB-500, fragment, human spinal cord — and note what each one is missing. Rat compression SCI study1 Rat Full-length Tβ4 Directly on-target injury, but rodent + parent protein TBI / stroke models289 Adjacent CNS injury, rodent + parent protein Neural progenitor cell assays610 Cultured cells Mechanism only; no organism outcome Ophthalmic Phase 2–3 trials1112 Human Full-length Tβ4 (eye drop) Human safety signal, but unrelated tissue; mixed efficacy TB-500 fragment CNS trials — Ac-LKKTETQ Do not exist So the honest evidence ladder for “TB-500 supports spinal cord regeneration” is: robust in-vitro mechanism → positive rodent SCI and CNS-injury studies (full-length Tβ4) → positive but tissue-unrelated human eye trials (also full-length, and mixed) → zero human spinal cord trials of either Tβ4 or the TB-500 fragment. Every rung people cite to build enthusiasm is one or two categories removed from the actual claim. That does not make the mechanism uninteresting; it makes the leap to human recommendation unsupported. The most defensible one-sentence summary a researcher can offer is: full-length thymosin beta-4 has produced encouraging but preliminary neuroprotective and remyelinating signals in rodent CNS-injury models, and whether those translate to humans — let alone to the marketed fragment — is entirely untested.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles